

# Mala K Maini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/662229/publications.pdf>

Version: 2024-02-01

125  
papers

13,299  
citations

26630

56  
h-index

24982

109  
g-index

134  
all docs

134  
docs citations

134  
times ranked

12788  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. <i>Journal of Experimental Medicine</i> , 2000, 191, 1269-1280.	8.5	761
2	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	27.6	643
3	Living in the liver: hepatic infections. <i>Nature Reviews Immunology</i> , 2012, 12, 201-213.	22.7	451
4	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. <i>Journal of Experimental Medicine</i> , 2007, 204, 667-680.	8.5	385
5	Incubation Phase of Acute Hepatitis B in Man: Dynamic of Cellular Immune Mechanisms. <i>Hepatology</i> , 2000, 32, 1117-1124.	7.3	359
6	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342
7	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. <i>Gastroenterology</i> , 1999, 117, 1386-1396.	1.3	331
8	Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2009, 137, 1289-1300.	1.3	324
9	IL-10-Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. <i>Journal of Immunology</i> , 2012, 189, 3925-3935.	0.8	310
10	Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. <i>Journal of Experimental Medicine</i> , 2013, 210, 99-114.	8.5	286
11	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. <i>Science</i> , 2021, 372, 1418-1423.	12.6	286
12	Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. <i>Hepatology</i> , 2011, 53, 1494-1503.	7.3	283
13	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. <i>Nature</i> , 2022, 601, 110-117.	27.8	280
14	IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. <i>Journal of Experimental Medicine</i> , 2017, 214, 1567-1580.	8.5	259
15	Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. <i>Science</i> , 2022, 377, .	12.6	241
16	Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2012, 7, e47648.	2.5	235
17	Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection. <i>PLoS Pathogens</i> , 2010, 6, e1001227.	4.7	228
18	Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. <i>Nature Medicine</i> , 2015, 21, 591-600.	30.7	226

#	ARTICLE	IF	CITATIONS
19	Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. <i>Journal of Experimental Medicine</i> , 2008, 205, 2111-2124.	8.5	220
20	CXCR6 marks a novel subset of T-bet <sup>lo</sup> Eomesin <sup>hi</sup> natural killer cells residing in human liver. <i>Scientific Reports</i> , 2016, 6, 26157.	3.3	220
21	Escaping High Viral Load Exhaustion. <i>Journal of Experimental Medicine</i> , 2002, 195, 1089-1101.	8.5	213
22	Modulation of the CD8 <sup>+</sup> -T-Cell Response by CD4 <sup>+</sup> CD25 <sup>+</sup> Regulatory T Cells in Patients with Hepatitis B Virus Infection. <i>Journal of Virology</i> , 2005, 79, 3322-3328.	3.4	212
23	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	3.7	208
24	Circulating and intrahepatic antiviral B cells are defective in hepatitis B. <i>Journal of Clinical Investigation</i> , 2018, 128, 4588-4603.	8.2	208
25	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 225-233.	3.7	202
26	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). <i>European Journal of Immunology</i> , 2021, 51, 2708-3145.	2.9	198
27	Liposomal amphotericin B in drug-resistant visceral leishmaniasis. <i>Lancet</i> , The, 1991, 337, 1061-1062.	13.7	191
28	Bim-mediated deletion of antigen-specific CD8 <sup>+</sup> T cells in patients unable to control HBV infection. <i>Journal of Clinical Investigation</i> , 2008, 118, 1835-1845.	8.2	187
29	Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. <i>Journal of Hepatology</i> , 2011, 55, 103-110.	3.7	183
30	The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003208.	4.7	176
31	Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 <sup>+</sup> T Cells in the Same Host. <i>Cell Reports</i> , 2016, 16, 1243-1252.	6.4	176
32	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. <i>Science Immunology</i> , 2020, 5, .	11.9	172
33	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. <i>Journal of Hepatology</i> , 2015, 62, 486-491.	3.7	160
34	Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 252-264.	1.2	154
35	The role of innate immunity in the immunopathology and treatment of HBV infection. <i>Journal of Hepatology</i> , 2016, 64, S60-S70.	3.7	150
36	Sestrins induce natural killer function in senescent-like CD8 <sup>+</sup> T cells. <i>Nature Immunology</i> , 2020, 21, 684-694.	14.5	139

#	ARTICLE	IF	CITATIONS
37	Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. <i>Journal of Immunology</i> , 2016, 197, 4283-4291.	0.8	125
38	T-cell clonality in immune responses. <i>Trends in Immunology</i> , 1999, 20, 262-266.	7.5	115
39	The molecular basis of the failed immune response in chronic HBV: Therapeutic implications. <i>Journal of Hepatology</i> , 2010, 52, 616-619.	3.7	115
40	Clonal Expansions in Acute EBV Infection Are Detectable in the CD8 and not the CD4 Subset and Persist with a Variable CD45 Phenotype. <i>Journal of Immunology</i> , 2000, 165, 5729-5737.	0.8	110
41	NK Cells: A Double-Edged Sword in Chronic Hepatitis B Virus Infection. <i>Frontiers in Immunology</i> , 2013, 4, 57.	4.8	103
42	Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. <i>Current Opinion in Immunology</i> , 2000, 12, 403-408.	5.5	100
43	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. <i>Lancet, The</i> , 2020, 395, 888-898.	13.7	98
44	HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently. <i>Journal of Immunology</i> , 2006, 176, 6130-6146.	0.8	97
45	The Host-Pathogen Interaction during HBV Infection: Immunological Controversies. <i>Antiviral Therapy</i> , 2010, 15, 15-24.	1.0	96
46	Optimal management of hepatitis B virus infection – EASL Special Conference. <i>Journal of Hepatology</i> , 2015, 63, 1238-1253.	3.7	91
47	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2022, 375, 183-192.	12.6	91
48	IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction. <i>Frontiers in Immunology</i> , 2018, 9, 1009.	4.8	88
49	Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 662-675.	17.8	87
50	Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men.. <i>Sexually Transmitted Infections</i> , 1996, 72, 27-31.	1.9	81
51	The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function. <i>Journal of Virology</i> , 2007, 81, 2940-2949.	3.4	80
52	Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 192-202.	8.1	75
53	Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	72
54	Fine needle aspirates comprehensively sample intrahepatic immunity. <i>Gut</i> , 2019, 68, 1493-1503.	12.1	65

#	ARTICLE	IF	CITATIONS
55	Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. <i>Current Opinion in Microbiology</i> , 2000, 3, 387-392.	5.1	64
56	Adaptive Reconfiguration of Natural Killer Cells in HIV-1 Infection. <i>Frontiers in Immunology</i> , 2018, 9, 474.	4.8	64
57	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. <i>EBioMedicine</i> , 2021, 65, 103259.	6.1	61
58	Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. <i>Hepatology</i> , 2021, 74, 55-71.	7.3	61
59	T cells in COVID-19 are united in diversity. <i>Nature Immunology</i> , 2020, 21, 1307-1308.	14.5	59
60	The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. <i>iScience</i> , 2021, 24, 103353.	4.1	57
61	Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. <i>Nature Communications</i> , 2021, 12, 2814.	12.8	54
62	Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. <i>PLoS Pathogens</i> , 2016, 12, e1005788.	4.7	54
63	Hepatitis B infection: current concepts and future challenges. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 109-113.	0.5	53
64	Human Liver Memory CD8+ T Cells Use Autophagy for Tissue Residence. <i>Cell Reports</i> , 2020, 30, 687-698.e6.	6.4	53
65	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL/AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	7.3	52
66	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2021, 74, 1064-1074.	3.7	52
67	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. <i>Lancet Microbe</i> , The, 2021, 2, e508-e517.	7.3	52
68	A comparison of two techniques for the molecular tracking of specific T cell responses; CD4+human T cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+population. <i>Immunology</i> , 1998, 94, 529-535.	4.4	48
69	Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. <i>Journal of Hepatology</i> , 2017, 67, 687-699.	3.7	47
70	CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2010, 53, 252-260.	3.7	46
71	T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. <i>European Journal of Immunology</i> , 2000, 30, 3067-3078.	2.9	45
72	Innate and Adaptive Immune Responses in Hepatitis B Virus Infection. <i>Digestive Diseases</i> , 2010, 28, 126-132.	1.9	45

#	ARTICLE	IF	CITATIONS
73	Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, 1372.	12.8	44
74	Effect of HIV Infection and Antiretroviral Therapy on Hepatitis B Virus (HBV)â€“Specific T Cell Responses in Patients Who Have Resolved HBV Infection. <i>Journal of Infectious Diseases</i> , 2005, 191, 1169-1179.	4.0	43
75	Greater CD8+ TCR Heterogeneity and Functional Flexibility in HIV-2 Compared to HIV-1 Infection. <i>Journal of Immunology</i> , 2003, 171, 307-316.	0.8	42
76	T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. <i>Journal of Immunology</i> , 2017, 198, 1172-1182.	0.8	41
77	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. <i>Gut</i> , 2018, 67, gutjnl-2017-314873.	12.1	40
78	Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. <i>International Immunology</i> , 1999, 11, 535-543.	4.0	39
79	Reconstitution of Hepatitis B Virus (HBV)â€“Specific T Cell Responses with Treatment of Human Immunodeficiency Virus/HBV Coinfection. <i>Journal of Infectious Diseases</i> , 2003, 188, 1815-1819.	4.0	36
80	Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections. <i>Cell Reports Medicine</i> , 2022, 3, 100557.	6.5	36
81	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. <i>Hepatology</i> , 2006, 43, 602-611.	7.3	35
82	T cell receptor-therapy in HBV-related hepatocellular carcinoma. <i>Oncolmmunology</i> , 2015, 4, e1008354.	4.6	34
83	Oxidative Stress Triggers Selective tRNA Retrograde Transport in Human Cells during the Integrated Stress Response. <i>Cell Reports</i> , 2019, 26, 3416-3428.e5.	6.4	34
84	Rare inborn errors associated with chronic hepatitis B virus infection*. <i>Hepatology</i> , 2012, 56, 1661-1670.	7.3	30
85	Cholesterol-modifying drugs in COVID-19. <i>Oxford Open Immunology</i> , 2020, 1, iqaa001.	2.8	27
86	Immuneâ€“Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis Bâ€“Infected Cells. <i>Hepatology</i> , 2020, 72, 1528-1540.	7.3	26
87	Platelets harness the immune response to drive liver cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 12840-12841.	7.1	25
88	Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	25
89	Natural Killer Cells in Liver Disease. <i>Seminars in Liver Disease</i> , 2017, 37, 198-209.	3.6	24
90	SARS-CoV-2â€“specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	24

#	ARTICLE	IF	CITATIONS
91	The past, current and future epidemiological dynamic of SARS-CoV-2. Oxford Open Immunology, 2022, 3, .	2.8	24
92	Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. Journal of Virology, 2016, 90, 8563-8574.	3.4	22
93	The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV. Vaccines, 2020, 8, 184.	4.4	21
94	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566.	8.2	20
95	Differences in the regulation of CD4 and CD8 T cell clones during immune responses. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 401-406.	4.0	19
96	Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. Mucosal Immunology, 2014, 7, 89-100.	6.0	19
97	The human liver microenvironment shapes the homing and function of CD4 <sup>+</sup> T-cell populations. Gut, 2022, 71, 1399-1411.	12.1	19
98	NK cells limit therapeutic vaccine-induced CD8 <sup>+</sup> T cell immunity in a PD-L1-dependent manner. Science Translational Medicine, 2022, 14, eabi4670.	12.4	19
99	HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology, 2022, 166, 68-77.	4.4	18
100	Defective natural killer cell anti-viral capacity in paediatric HBV infection. Clinical and Experimental Immunology, 2015, 179, 466-476.	2.6	16
101	Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. Journal of Hepatology, 2022, 77, 525-538.	3.7	16
102	Licensing Virus-Specific T Cells to Secrete the Neutrophil Attracting Chemokine CXCL-8 during Hepatitis B Virus Infection. PLoS ONE, 2011, 6, e23330.	2.5	15
103	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Scientific Reports, 2017, 7, 5514.	3.3	14
104	CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity. Molecular Therapy - Methods and Clinical Development, 2020, 19, 149-161.	4.1	14
105	Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID-19. Immunological Reviews, 2021, 299, 108-117.	6.0	14
106	Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study. BMC Infectious Diseases, 2015, 15, 138.	2.9	13
107	Global and immunotherapeutic insights into hepatitis B. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 71-72.	17.8	13
108	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. Frontiers in Oncology, 2020, 10, 971.	2.8	10

#	ARTICLE	IF	CITATIONS
109	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. <i>Science</i> , 2021, , eabm0811.	12.6	10
110	Liver-resident memory T cells: life in lockdown. <i>Seminars in Immunopathology</i> , 2022, 44, 813-825.	6.1	10
111	Regulation of apoptosis and replicative senescence in CD8+ T cells from patients with viral infections. <i>Biochemical Society Transactions</i> , 2000, 28, 255-258.	3.4	8
112	IL-2â€“Engineered nano-APC Effectively Activates Viral Antigen-Mediated T Cell Responses from Chronic Hepatitis B Virus-Infected Patients. <i>Journal of Immunology</i> , 2012, 188, 1534-1543.	0.8	8
113	Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance. <i>Journal of Hepatology</i> , 2014, 61, 459-461.	3.7	8
114	Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 129.	4.8	7
115	HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory TÂ€cells. <i>Cell Reports</i> , 2022, 39, 110650.	6.4	6
116	Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 11-17.	1.8	5
117	Pathogenesis of hepatitis B virus infection and potential for new therapies. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, 581-584.	0.5	4
118	Liver-resident CD8+ T cells: Learning lessons from the local experts. <i>Journal of Hepatology</i> , 2020, 72, 1049-1051.	3.7	4
119	Reply to: â€œTo target or not to target viral antigens in HBV related HCC?â€ Journal of Hepatology, 2015, 62, 1450-1452.	3.7	3
120	FRI-162-Prime-boost vaccination strategies using chimpanzee-Adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice. <i>Journal of Hepatology</i> , 2019, 70, e459-e460.	3.7	2
121	CD8+ T cells cure without killing. <i>Nature Reviews Immunology</i> , 2019, 19, 201-201.	22.7	2
122	Isolation of human intrahepatic leukocytes for phenotypic and functional characterization by flow cytometry. <i>STAR Protocols</i> , 2022, 3, 101356.	1.2	2
123	Shared immunotherapeutic approaches in HIV and hepatitis B virus. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 157-164.	3.8	1
124	The Effects of Pathogens on the Immune System: Viral Hepatitis. , 2006, , 233-254.		0
125	Immunity to Oncogenic Viruses. , 2016, , 363-374.		0